Prophylaxis of oropharyngeal candidiasis with clotrimazole.
A total of 202 evaluable cancer patients were randomly assigned to receive or not receive oral clotrimazole as antifungal prophylaxis during hospitalization. Oropharyngeal candidiasis occurred in 1% of the former patients and 27% of the latter patients (P less than .00001). Candida sp were cultured from the initial throat specimens of 53 control patients and 55 patients who received prophylaxis. Oropharyngeal candidiasis subsequently developed in 2% of the former patients and 38% of the latter patients (P = less than .00001). Oral clotrimazole is an effective agent for prophylaxis of oropharyngeal candidiasis in susceptible cancer patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D002177:Candidiasis / Q000382:microbiology / Q000517:prevention & control*; D002180:Candidiasis, Oral / Q000517:prevention & control; D003022:Clotrimazole / Q000627:therapeutic use*; D004198:Disease Susceptibility; D005260:Female; D006760:Hospitalization; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009960:Oropharynx / Q000382:microbiology; D010608:Pharyngeal Diseases / Q000517:prevention & control*; D011897:Random Allocation; D012306:Risk
D000970:Antineoplastic Agents; D007093:Imidazoles; D003022:Clotrimazole